Hims & Hers Health, Inc. (HIMS) Announced Q2 2026 Earnings on August 10, 2026, Reporting "In the second quarter, revenue grew nearly 40% year-over-year to more than $753 million."

Hims & Hers Health, Inc. reported that in the second quarter, "revenue grew nearly 40% year-over-year to more than $753 million". U.S. operations generated "$622 million of revenue", representing "domestic revenue growth" of "16% year-over-year", while international revenue increased over 17-fold year-over-year to "$131 million". Adjusted EBITDA for the second quarter was "$60 million, representing an 8% adjusted EBITDA margin". These financial results exclude approximately "$81 million of nonrecurring costs" incurred during the quarter. GAAP net income for the second quarter was a loss of "$86 million", impacted by nonrecurring acquisition, restructuring, and legal costs.

Gross margins in the second quarter were "64%, down approximately 6 points quarter-over-quarter on an adjusted basis". During the quarter, operating cash flow was "negative $36 million" and free cash flow was "negative $68 million".The company ended the quarter with "nearly 3 million subscribers" on its platform, having added "300,000 net new subscribers" in the second quarter.

Management emphasized the company's investment in artificial intelligence, highlighting the phased rollout of a new AI-native care experience for Hers weight loss customers that has reduced nonclinical tasks handled by support teams by "nearly 50%", with AI answering "80% of their questions" to support their treatment journey. To accelerate these efforts, the company plans to open an "AI R&D lab in Menlo Park". In other specialties, testosterone is scaling "faster than any other specialty outside of weight loss", with plans to expand into "injectable and oral TRT" before the end of the year.

Additionally, Hims & Hers is developing a "best-in-class peptides experience" and plans to offer access to allowed peptides such as sermorelin, glutathione, and NAD+ "before the end of the year". The company also closed its acquisition of Eucalyptus in June, which contributed "approximately $40 million of revenue in the second quarter". On the regulatory side, the Federal Trade Commission filed a complaint against the company on July 29, which the company intends to "defend vigorously".Looking ahead, management raised its "2026 revenue outlook to $3.1 billion to $3.3 billion", representing a "year-over-year increase of 32% to 41%". The company expects full year 2026 adjusted EBITDA to be "between $275 million and $325 million", representing "an adjusted EBITDA margin of 9% at the midpoint of both ranges". For the third quarter, the company anticipates revenue in the range of "$880 million to $900 million", representing "a year-over-year increase of approximately 47% to 50%", and adjusted EBITDA of "$75 million to $95 million". Management also expects its international business to generate "at least $600 million of revenue in 2026", while continuing to operate "at or near breakeven on an adjusted EBITDA basis".

What is The Earnings Debate?

We turn quarterly earnings calls into a fast-paced financial comedic debate. Our AI hosts (one skeptic and one optimist) agree on almost nothing. We cut through jargon, pressure-test claims, and spotlight the questions that matter. Rigorous analysis. Actual laughs.
On the beat so you don't miss a beat.